犬の慢性腎臓病マーカーとして尿中アンモニアを提案(Ammonia Levels in Urine Could Serve as Marker for Chronic Kidney Disease in Dogs)

ad

2026-05-28 ノースカロライナ州立大学(NC State)

米ノースカロライナ州立大学(NC State University)の研究チームは、犬の尿中アンモニア濃度が慢性腎臓病(CKD)の早期診断や病状評価の指標として利用できる可能性を明らかにした。慢性腎臓病は高齢犬に多く見られる進行性疾患であり、早期発見が治療効果や生活の質の維持に重要である。研究では健康な犬と慢性腎臓病の犬の尿サンプルを比較した結果、腎機能が低下した犬では尿中アンモニア濃度が有意に低下していることが判明した。アンモニア排泄は体内の酸塩基平衡を維持する腎臓の重要な機能の一つであり、その低下は腎機能障害の進行を反映している可能性がある。研究者らは、尿中アンモニア測定が既存の血液検査や尿検査を補完し、病期判定や治療効果の評価にも役立つと考えている。本成果は獣医腎臓学における新たなバイオマーカー候補を提示するものであり、犬の慢性腎臓病の診断精度向上と適切な治療介入につながることが期待される。

<関連情報>

安定した慢性腎臓病の犬におけるアンモニア排泄障害と生存率との関連性 Association of impaired ammonia excretion with survival in dogs with stable chronic kidney disease

Autumn N Harris,Alexis Cooper,Rebeca A Castro,Andrew J Specht,Shelly L Vaden,Kirsten L Cooke
Journal of Veterinary Internal Medicine  Published:28 May 2026
DOI:https://doi.org/10.1093/jvimsj/aalag100

犬の慢性腎臓病マーカーとして尿中アンモニアを提案(Ammonia Levels in Urine Could Serve as Marker for Chronic Kidney Disease in Dogs)

Abstract

Background

In people with chronic kidney disease (CKD), inadequate renal ammonia excretion contributes to metabolic acidosis and is associated with worse outcomes. However, the prognostic relevance of ammonia excretion in dogs with CKD remains unclear.

Hypothesis/Objectives

A reduced urine ammonia-to-creatinine ratio (UACR) would be associated with shorter survival and faster disease progression in dogs with stable CKD.

Animals

Fifty client-owned dogs with International Renal Interest Society (IRIS) stages II-IV CKD receiving a therapeutic renal diet.

Methods

Prospective, observational longitudinal study. Dogs were followed for up to 12 months or until death. Progressive CKD was defined as a > 25% increase in serum creatinine from baseline. Dogs were categorized based on UACR < 2.0 or ≥ 2.0. Associations with survival and CKD progression were assessed using Cox proportional hazards and Kaplan–Meier analyses.

Results

Most dogs were IRIS stage II (41/50, 82%). Dogs with UACR < 2.0 at enrollment had a significantly greater risk of death (HR 3.045; 95% CI, 1.372-7.102) and shorter median survival (189 vs 445 days, P = .008). Dogs with UACR < 2.0 also had a significantly shorter time to CKD progression (median 132 vs 445 days; P = .0002). In addition, UPC ratio < 1.0 was associated with a lower risk of death (HR 0.351; 95% CI, 0.142-0.879).

Conclusions and clinical importance

Lower UACR (<2.0) was associated with higher case fatality and faster disease progression in dogs with azotemic CKD. Urine ammonia-to-creatinine ratio might be a useful biomarker for identifying dogs which could benefit from alkali therapy.

医療・健康
ad
ad
Follow
ad
タイトルとURLをコピーしました